In Phase II, what is the primary consideration for dosing and regimen?

• A. To determine the doses and regimen for Phase III
• B. To study pharmacokinetics in animals
• C. To evaluate marketing potential
• D. To implement post-marketing surveillance

Answer: (A)

In Phase II, the focus is on finding the right dose and dosing schedule to carry forward into larger confirmatory testing. The goal is dose-ranging: identify a dose (or doses) and regimen that show a meaningful effect while keeping safety and tolerability acceptable, so a recommended regimen can be used in Phase III. This sets up Phase III to verify efficacy and safety in a larger population using the chosen dosing plan.

Nonclinical pharmacokinetics in animals belong to earlier development, not Phase II. Marketing potential is not assessed in Phase II trials, and post-marketing surveillance occurs after approval in Phase IV.